🙌It’s our 7th anniversary today–and we have lots to celebrate 🥂 including: 1️⃣ #TeamElegen and all we’ve accomplished! ELEGEN's cell-free genesynthesis platform produces ENFINIA DNA with industry-leading length, complexity, purity and speed. 2️⃣Our investors, who believe in our mission to manufacture next-generation #longDNA, with high quality and speed, that can go directly into experiments, no cloning required. 3️⃣Our early access and pharma partners, including GSK, who provide valuable feedback helping us hone ENFINIA DNA to speed R&D and clinical workflows. https://bit.ly/3Y1gHQk #HappyAnniversary #nextgenDNA #genesynthesis #EnfiniaDNA
ELEGEN’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> CytomX’s Amgen-partnered T cell engager yields mixed Phase 1 data >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #pharma #healthcare
-
Thoughts on this? >> BrainStorm puts together plan for new Phase 3b ALS trial after pulling previous filing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #productmarketing
In what may be its final attempt, BrainStorm outlines Phase 3b plans for ALS cell therapy
https://endpts.com
-
🎉 Highlighting Innovation at the 9th RSC-BMCS Fragment-based Drug Discovery Meeting! 🎉 We're thrilled to share that CHARM Therapeutics is playing a pivotal role at the 9th RSC-BMCS Fragment-based Drug Discovery meeting, taking place today and tomorrow! Geoffrey Smith from our Medicinal Chemistry team will be presenting our cutting-edge research through an engaging poster presentation. 🔍 This event is a cornerstone for those passionate about advancing fragment-based drug discovery. Our involvement underscores the innovative approaches and hard work our team dedicates to pushing the boundaries of what's possible in the field. 🌐 Geoffrey's presentation is not just about showcasing our latest findings; it's about fostering a community of collaboration, insight sharing, and professional growth. We're leveraging LinkedIn to connect with like-minded professionals and industry leaders, making every interaction count. 👏 Please join us in supporting Geoffrey and the CHARM Therapeutics team. Your engagement—likes, shares, and comments—will not only elevate our research but also strengthen the ties within our scientific community. Let's make #Fragments24 a memorable event by spreading the word and celebrating the innovations that drive us forward. #Fragments24 #RSCBMCS #FragmentBasedDrugDiscovery #CHARMTherapeutics #ScienceImpact #PosterPresentation #Networking
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> BrainStorm puts together plan for new Phase 3b ALS trial after pulling previous filing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #productmarketing #pharma
In what may be its final attempt, BrainStorm outlines Phase 3b plans for ALS cell therapy
https://endpts.com
-
Addressing the pivotal issue of species differences between animals and humans, which contributes to the high failure rate of approximately 90% in clinical trials for drug candidates. It's time for a change. Our Organ-Chips emulate human responses more accurately than traditional models, enabling the advancement of superior drug candidates to clinical trials. Partner with our expert team to de-risk your drug development pipeline through a range of Organ-on-a-Chip compound testing services. Let's revolutionize drug development together. #Myopharm #DrugDevelopment #InnovationInHealthcare #OrganOnAChip
-
-
Strategic, Transformational and Delivery Focused Technology & Business Pharmaceutical R&D Leader
🔬Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing therapeutics in immuno-dermatology, recently implemented Instem's ACCEL, a cutting-edge solution designed to centralize and transform statistical analysis and reporting. Dermavant Sciences chose ACCEL for its robust capabilities and seamless integration, aiming to enhance their drug development programs without disrupting ongoing projects. This case study underscores the importance of how strategic partnerships can lead to breakthroughs in operational efficiency and program success. ➡️ Are you ready to revolutionize your data management processes? Discover how Instem's ACCEL can be the game-changer for your organization! Download the case study here: https://lnkd.in/e3fmwEgH or DM for more information. #PharmaceuticalInnovation #ClinicalTrials #DataManagement #Instem #ACCEL
CASE STUDY
go.instem.com
-
GSK set to buy Aiolos Bio for $1.4B! Wow that was fast... Aiolos only closed its mammoth $245M Series A in October 2023. Another great news story for early Biotech buyouts, and hopefully something else that VC investors can get excited about. Aiolos is a clinical-stage company developing innovative therapies for respiratory and inflammatory conditions. AIO-001, which is ready to enter phase 2 trials for adult asthma patients, represents a potentially best-in-class medicine targeting the TSLP pathway. A nice bolt-on deal for GSK, which already generates $14B+ in revenue from its respiratory medicines and vaccines (2022), and hopefully more encouraging news for asthma patients. 2024 is warming up! #respiratory #asthma #mergersandacquisitions https://lnkd.in/gHJDKN2B
GSK to acquire Aiolos Bio in $1.4 bln deal
reuters.com
-
Pitt Street Research publishes an initiation report on Dimerix Limited - a clinical stage drug developer which is developing DMX-200 for kidney diseases. DMX-200 is in a Phase 3 trial for FSGS (Focal Segmental Glomerulosclerosis) and has completed a Phase 2 study for diabetic kidney disease. The company is expecting initial analysis in mid-March and could submit for conditional marketing approval in CY24, subject to successful results. It has secured a licensing deal with Advanz Pharma that could bring A$230m in milestone payments, plus royalties on sales. Notwithstanding all this, it is still priced like a Phase 2 company - we value DXB was A$0.58 per share in our base case scenario and A$0.77 in our bull case scenario, equating to equity values of A$246.3m and A$326.3m which are more in line with the valuation of ASX biotechs at Phase 3. Please be advised that this report is General Advice only and is a report commissioned by the Company. Please see p.20 for the key risks and the final page for the full General Advice Warning, disclosures and disclaimers. Marc Kennis Stuart Roberts Mark Diamond Nina Webster Hugh Alsop Clinton Snow Sonia Poli Hamish George #dimerix #dxb200 #kidneyhealth #kidneydisease #biotech #biotechs #biotechstocks #healthstocks #ASX #equities #equityresearch #researchreport #researchinitiation https://lnkd.in/eyjWtZ8T
Dimerix — Pitt Street Research | Stock research
pittstreetresearch.com
-
Thoughts on this? >> Of the few preclinical IPOs, Metagenomi keeps details about IND plans close >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #pharmaceutical #healthcare
Of the few preclinical IPOs, Metagenomi keeps details about IND plans close
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Of the few preclinical IPOs, Metagenomi keeps details about IND plans close >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #biotech #pharma
Of the few preclinical IPOs, Metagenomi keeps details about IND plans close
https://endpts.com
